Published: September 3, 2018

Modulating BET bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE.AI, an artificial intelligence platform (Advanced Therapeutics, Aug 2018)

Modulating BET bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE.AI, an artificial intelligence platform

Pantuck AJ, Lee D, Kee T, Wang P, Lakhotia S, Silverman MH, Mathis C, Drakaki A, Belldegrun AS, Ho C and Ho D.

Abstract
Combination chemotherapy is a cornerstone of cancer treatment. Optimizing its effectiveness requires dose‐ and time‐dependent regulation of drug synergy. In this report, CURATE.AI, an artificial intelligence platform, is used to prospectively guide the dosing of a bromodomain inhibitor (ZEN‐3694) and enzalutamide administered in combination to a patient with metastatic castration‐resistant prostate cancer to reduce serum prostate‐specific antigen (PSA) levels. CURATE.AI successfully identifies substantial ZEN‐3694 and enzalutamide dose adjustments, increasing both treatment efficacy and tolerance. CURATE.AI analysis also confirms that the patient’s durable response is mediated by ZEN‐3694 inclusion in the regimen. Due to CURATE.AI‐enhanced efficacy and safety, the patient was able to continue with the combination regimen, resulting in a durable response and no disease progression based on CURATE.AI‐sustained control over PSA levels and reduced lesion size.

Please click HERE for the research article.